Abstract
Supportive care is an essential component of cancer treatment. Prevention of febrile neutropenia, chemotherapy-induced nausea/vomiting, anemia, and osteoporosis are discussed in this chapter. Solutions in countries with limited resources are mentioned. Lifestyle management and drugs are key factors. Improving quality of life for the cancer patient is the goal of supportive care, and this may also positively impact survival.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aapro MS (2012) Supportive care and palliative care: a time for unity in diversity. Ann Oncol 23(8):1932–1934
Naeim A, Aapro M, Subbarao R, Balducci L (2014) Supportive care considerations for older adults with cancer. J Clin Oncol 32(24):2627–2642
Cardoso F, Bese N, Distelhorst SR et al (2013) Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. Breast 22(5):593–605
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243
Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26(6):1045–1047
Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32
Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients. Available from: www.guidance.nice.org.uk/cg151. Last accessed 4 Jan 2015
Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051
de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F (2010) Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 21(Suppl 5):v252–v256
Correia A, Azevedo Mdo S, Gondim F, Bandeira F (2014) Ethnic aspects of vitamin D deficiency. Arq Bras Endocrinol Metabol 58(5):540–544
Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18(8):1033–1046
LeBlanc ES, Nielson CM, Marshall LM, Lapidus JA, Barrett-Connor E, Ensrud KE et al (2009) The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab 94(9):3337–3346
Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA et al (2012) A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 367(1):40–44
Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J, ESMO Guidelines Working Group (2014) Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 25(Suppl 3):iii124–iii137
Koo K, Lam K, Mittmann N, Konski A, Dennis K, Zeng L et al (2013) Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases. Support Care Cancer 21(6):1785–1791
Coleman RE, Gnant M, Paterson A (2013) Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials. SABCS 2013; San Antonio Breast Cancer Symposium. San Antonio, Texas, USA
Schrijvers D, De Samblanx H, Roila F, ESMO Guidelines Working Group (2010) Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 21(Suppl 5):v244–v247
Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P, European Organisation for Research and Treatment of Cancer (EORTC) (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43(2):258–270
Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y (2012) Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 23(8):1954–1962
Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B (2012) Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 106(7):1249–1258
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Aapro, M. (2015). Supportive Care. In: Droz, JP., Carme, B., Couppié, P., Nacher, M., Thiéblemont, C. (eds) Tropical Hemato-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-18257-5_56
Download citation
DOI: https://doi.org/10.1007/978-3-319-18257-5_56
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-18256-8
Online ISBN: 978-3-319-18257-5
eBook Packages: MedicineMedicine (R0)